MHRA — authorised 28 January 2022
- Marketing authorisation holder: Pfizer Europe MA EEIG
- Status: approved
🇬🇧 Paxlovid (Copackaged) in United Kingdom
MHRA authorised Paxlovid (Copackaged) on 28 January 2022 · NICE has issued 1 UK HTA decision
Marketing authorisation
Health technology assessment
1 decision from NICE for Paxlovid (Copackaged) in United Kingdom.
NICE TA878 — ✓ Recommended
- Indication assessed: treating COVID-19
NICE recommended Paxlovid (Copackaged) for treating COVID-19. This decision was made based on a commercial arrangement, which suggests that the drug's price was negotiated with the manufacturer. No restrictions were placed on the use of Paxlovid (Copackaged) as part of this recommendation.
Paxlovid (Copackaged) in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United Kingdom
Frequently asked questions
Is Paxlovid (Copackaged) approved in United Kingdom?
Yes. MHRA authorised it on 28 January 2022.
Who is the marketing authorisation holder for Paxlovid (Copackaged) in United Kingdom?
Pfizer Europe MA EEIG holds the UK marketing authorisation.
Has Paxlovid (Copackaged) been assessed by UK health technology agencies?
Yes — 1 UK HTA decision on record from NICE.